{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T18:38:01Z","timestamp":1776451081091,"version":"3.51.2"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Accuracy in in vivo assessment of human epidermal growth factor receptor type 2 (HER2) status is crucial for predicting the response to HER2-targeted therapies in breast cancer. This study assessed the safety, feasibility, and diagnostic accuracy of <jats:sup>99m<\/jats:sup>Tc-ABH2, a reengineered affibody molecule with radionuclide labeling, for HER2 expression in breast cancer using SPECT\/CT imaging, compared with <jats:sup>18<\/jats:sup>F-FDG PET\/CT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>Thirty-six patients suspected of primary breast cancer were enrolled in this prospective, single-center study from March to July in 2023. Each participant underwent SPECT\/CT imaging with <jats:sup>99m<\/jats:sup>Tc-ABH2 SPECT\/CT and <jats:sup>18<\/jats:sup>F-FDG PET\/CT. The imaging results were validated against immunohistochemistry and fluorescence in situ hybridization, employing visual scores and quantitative values for analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Optimal imaging contrast was observed around 2 hours postinjection of <jats:sup>99m<\/jats:sup>Tc-ABH2. Among the evaluated 27 patients with immunohistochemistry and fluorescence in situ hybridization findings, the <jats:sup>99m<\/jats:sup>Tc-ABH2 SPECT\/CT visual evaluation displayed a sensitivity of 71.4%, specificity of 72.2%, and accuracy of 71.9%. Using an SUV<jats:sub>max<\/jats:sub> cutoff of 2.32, the sensitivity, specificity, and accuracy for detecting HER2 status were 92.86%, 72.22%, and 81.25%, respectively. Notably, <jats:sup>99m<\/jats:sup>Tc-ABH2 precisely identified all immunohistochemistry (3+) tumors and showed increased uptake in bone and lymph node metastases. Meanwhile, <jats:sup>18<\/jats:sup>F-FDG PET\/CT showed no significant difference in uptake between HER2 (2+\/3+) and HER2 (0\/1+) tumors (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.81).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study validated <jats:sup>99m<\/jats:sup>Tc-ABH2 SPECT\/CT as a promising diagnostic tool for precise HER2 assessment. The robust sensitivity for immunohistochemistry (3+) tumors and the visualization of metastases highlight its diagnostic significance, potentially impacting patient outcomes positively.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005535","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T17:00:53Z","timestamp":1732294853000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["HER2-Targeted Affibody Molecule 99mTc-ABH2 for Imaging HER2 Expression in Breast Cancer"],"prefix":"10.1097","author":[{"given":"Xiaona","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiong","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongli","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"bib1-20250107","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","year":"1987","journal-title":"Science"},{"key":"bib2-20250107","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","year":"2001","journal-title":"N Engl J Med"},{"key":"bib3-20250107","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"bib4-20250107","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.22.00519","article-title":"Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update","volume":"40","year":"2022","journal-title":"J Clin Oncol"},{"key":"bib5-20250107","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","year":"2020","journal-title":"Lancet Oncol"},{"key":"bib6-20250107","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1634\/theoncologist.2019-0446","article-title":"De novo versus recurrent HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from the SystHERs registry","volume":"25","year":"2020","journal-title":"Oncologist"},{"key":"bib7-20250107","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib8-20250107","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1200\/JCO.2011.37.2482","article-title":"Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib9-20250107","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1016\/j.ejca.2014.08.014","article-title":"Breast cancer during follow-up and progression\u2014a population based cohort on new cancers and changed biology","volume":"50","year":"2014","journal-title":"Eur J Cancer"},{"key":"bib10-20250107","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.semcancer.2020.10.005","article-title":"The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer","volume":"72","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"bib11-20250107","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.3390\/jcm12154882","article-title":"PET\/CT and SPECT\/CT imaging of HER2-positive breast cancer","volume":"12","year":"2023","journal-title":"J Clin Med"},{"key":"bib12-20250107","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.123.266392","article-title":"First-in-human evaluation of site-specifically labeled 89Zr-pertuzumab in patients with HER2-positive breast cancer","volume":"65","year":"2024","journal-title":"J Nucl Med"},{"key":"bib13-20250107","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/0008-5472.CAN-05-3521","article-title":"Tumor imaging using a picomolar affinity HER2 binding affibody molecule","volume":"66","year":"2006","journal-title":"Cancer Res"},{"key":"bib14-20250107","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1007\/s00259-020-04754-6","article-title":"Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe 99mTc-HYNIC-H10F","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib15-20250107","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1007\/s00259-023-06232-1","article-title":"Comparison of renal clearance of [(18)F]AlF-RESCA-HER2-BCH and [(18)F]AlF-NOTA-HER2-BCH in mice and breast cancer patients","volume":"50","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib16-20250107","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7150\/thno.13502","article-title":"Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 Affibody PET\/CT","volume":"6","year":"2016","journal-title":"Theranostics"},{"key":"bib17-20250107","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.7150\/thno.86770","article-title":"Phase I clinical evaluation of 99mTc-labeled affibody molecule for imaging HER2 expression in breast cancer","volume":"13","year":"2023","journal-title":"Theranostics"},{"key":"bib18-20250107","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2967\/jnumed.113.131243","article-title":"First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule","volume":"55","year":"2014","journal-title":"J Nucl Med"},{"key":"bib19-20250107","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/MNM.0000000000001660","article-title":"Radiosynthesis, optimization and pharmacokinetic study of the 99mTc-labeled human epidermal growth factor receptor 2 affibody molecule probe 99m Tc-(HE)3 ZHER2:V2","volume":"44","year":"2023","journal-title":"Nucl Med Commun"},{"key":"bib20-20250107","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/S1470-2045(20)30751-8","article-title":"Medical imaging and nuclear medicine: a lancet oncology commission","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"key":"bib21-20250107","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.2967\/jnumed.119.236943","article-title":"SPECT\/CT: standing on the shoulders of giants, it is time to reach for the sky!","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"bib22-20250107","doi-asserted-by":"crossref","first-page":"892","DOI":"10.2967\/jnumed.109.073239","article-title":"Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules","volume":"51","year":"2010","journal-title":"J Nucl Med"},{"key":"bib23-20250107","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"bib24-20250107","first-page":"1","article-title":"Examination of low ERBB2 protein expression in breast cancer tissue","volume":"8","year":"2022","journal-title":"JAMA Oncol"},{"key":"bib25-20250107","doi-asserted-by":"crossref","first-page":"100032","DOI":"10.1016\/j.modpat.2022.100032","article-title":"Multi-institutional assessment of pathologist scoring HER2 immunohistochemistry","volume":"36","year":"2023","journal-title":"Mod Pathol"},{"key":"bib26-20250107","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:44Z","timestamp":1736294444000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":26,"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005535","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,18]]}}}